Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18830655 | 0.82 | ADRA2A (0.41) | ADRA2ATLR8ALDH1A1MAPTTDP1 | |
| SCHEMBL27893457 | 0.78 | THRB (0.53) | ADRA2ATLR8ALDH1A1MAPTTDP1 | |
| SCHEMBL10394666 | 0.78 | ALDH1A1 (0.68) | ALDH1A1MAPTTDP1L3MBTL1ABL1 | |
| SCHEMBL19035330 | 0.77 | ADRA2A (0.39) | ADRA2ATLR8ALDH1A1MAPTTDP1 | |
| SCHEMBL8746003 | 0.77 | ALDH1A1 (0.47) | ALDH1A1MAPTL3MBTL1SOS1HTT | |
| SCHEMBL20564038 | 0.76 | MAPT (0.44) | ADRA2ATLR8ALDH1A1MAPTTDP1 | |
| SCHEMBL19035336 | 0.76 | MAPT (0.41) | ADRA2ATLR8ALDH1A1MAPTTDP1 | |
| SCHEMBL3400985 | 0.75 | ADRA2A (0.53) | ADRA2AALDH1A1ABL1KCNH3TSHR | |
| SCHEMBL26325050 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPTABL1KCNH3HTT | |
| SCHEMBL21872424 | 0.74 | TLR8 (0.43) | TLR8ALDH1A1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2018213572-A9 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018213572-A1 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | PNMT, NCL, NPM1 | ADRA2A 2424/4885TLR8 3085/4885ALDH1A1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.